Merck has restructured its co-development and commercialization agreement with Ariad Pharmaceuticals, Inc., obtaining an exclusive license to ridaforolimus, an investigational, oral mTOR inhibitor in development for the treatment of multiple types of cancer. Merck now has acquired full control of the development and worldwide commercialization of ridaforolimus. Ariad will receive a $50 million upfront fee and is eligible to receive milestone payments associated with regulatory filings and app...